Aztreonam
- Generic Name
- Aztreonam
- Brand Names
- Azactam, Cayston
- Drug Type
- Small Molecule
- Chemical Formula
- C13H17N5O8S2
- CAS Number
- 78110-38-0
- Unique Ingredient Identifier
- G2B4VE5GH8
- Background
A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
- Indication
For the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections.
- Associated Conditions
- Bone and Joint Infections, Cystic Fibrosis (CF), Febrile Neutropenia, Gynecological Infection, Intraabdominal Infections, Lower Respiratory Tract Infection (LRTI), Osteomyelitis, Septic Arthritis, Septicemia, Skin Infections, Urinary Tract Infection, Uncomplicated Gonorrhea
Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 5
- Registration Number
- NCT02730793
- Locations
- 🇺🇸
Children's Hospital of Richmond at VCU, Richmond, Virginia, United States
Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
- Conditions
- Pseudomonas Aeruginosa in Cystic Fibrosis
- Interventions
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 409
- Registration Number
- NCT02449031
- Locations
- 🇺🇸
Novartis Investigative Site, Spokane, Washington, United States
Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)
- Conditions
- Skin Diseases, InfectiousSkin Diseases, Bacterial
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 120
- Registration Number
- NCT02276482
Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
- Conditions
- Complicated Skin and Soft Tissue Infection
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT02202135
- Locations
- 🇹🇷
Research site, Izmir, Turkey
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
- Conditions
- Skin Structures and Soft Tissue InfectionsSkin and Subcutaneous Tissue Bacterial Infections
- Interventions
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 850
- Registration Number
- NCT01984684
- Locations
- 🇨🇳
Melinta 303 Study Site, Zhonghe, Taiwan
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
- Interventions
- First Posted Date
- 2013-03-15
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 660
- Registration Number
- NCT01811732
- Locations
- 🇺🇦
Melinta Investigational Site, Zaporizhzhia, Ukraine
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
- Conditions
- Bacterial InfectionsComplicated Infection
- Interventions
- Drug: combination of Aztreonam - Avibactam (ATM-AVI)Drug: Placebo
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 222
- Registration Number
- NCT01689207
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
- Conditions
- Infection
- Interventions
- Drug: trimethoprim-sulfamethoxazole
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 563
- Registration Number
- NCT01659866
- Locations
- 🇺🇸
Northwestern University Department of Urology, Chicago, Illinois, United States
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 107
- Registration Number
- NCT01641822
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
- Conditions
- Complicated Skin and Soft Tissue Infection
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 802
- Registration Number
- NCT01499277
- Locations
- 🇺🇦
Research Site, Odesa, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.